CN113056457B - 用于治疗cns疾病的前药 - Google Patents

用于治疗cns疾病的前药 Download PDF

Info

Publication number
CN113056457B
CN113056457B CN201980075181.5A CN201980075181A CN113056457B CN 113056457 B CN113056457 B CN 113056457B CN 201980075181 A CN201980075181 A CN 201980075181A CN 113056457 B CN113056457 B CN 113056457B
Authority
CN
China
Prior art keywords
methyl
inden
dihydro
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980075181.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056457A (zh
Inventor
M·F·贾科布森
M·约尔根森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN113056457A publication Critical patent/CN113056457A/zh
Application granted granted Critical
Publication of CN113056457B publication Critical patent/CN113056457B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980075181.5A 2018-12-03 2019-11-27 用于治疗cns疾病的前药 Active CN113056457B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201800947 2018-12-03
DKPA201800947 2018-12-03
PCT/EP2019/082715 WO2020114853A1 (en) 2018-12-03 2019-11-27 Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Publications (2)

Publication Number Publication Date
CN113056457A CN113056457A (zh) 2021-06-29
CN113056457B true CN113056457B (zh) 2025-06-20

Family

ID=69061245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980075181.5A Active CN113056457B (zh) 2018-12-03 2019-11-27 用于治疗cns疾病的前药

Country Status (5)

Country Link
US (2) US11535600B2 (cg-RX-API-DMAC7.html)
EP (1) EP3891134A1 (cg-RX-API-DMAC7.html)
JP (1) JP7583719B2 (cg-RX-API-DMAC7.html)
CN (1) CN113056457B (cg-RX-API-DMAC7.html)
WO (1) WO2020114853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010192A1 (en) * 1990-12-04 1992-06-25 H. Lundbeck A/S Indan derivatives
WO2005016901A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
HU198005B (en) 1984-12-04 1989-07-28 Sandoz Ag Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
JP2001517666A (ja) 1997-09-23 2001-10-09 藤沢薬品工業株式会社 チアゾール誘導体
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
CA2569843A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
JP2008530039A (ja) 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−1−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−3,3−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
EP2998288B1 (en) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
MX2010012037A (es) 2008-05-07 2010-11-30 Lundbeck & Co As H Composiciones y uso utiles para tratar trastornos cognitivos.
JP2012504560A (ja) 2008-10-03 2012-02-23 ハー・ルンドベック・アクチエゼルスカベット 経口製剤
EP2362865A2 (en) 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
JP2012506904A (ja) 2008-10-28 2012-03-22 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 難水溶性成分のためのメソ多孔性材料賦形剤
TW201102370A (en) * 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2639216B1 (en) 2010-11-09 2018-07-11 Kaneka Corporation Halogenated indenones and method for producing optically active indanones or optically active indanols by using same
EP2661427A1 (en) 2011-01-07 2013-11-13 H. Lundbeck A/S Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine
US9359376B2 (en) 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
LT3135656T (lt) 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
EP2903979B1 (en) * 2012-10-04 2020-08-19 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
CA2893256A1 (en) * 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
CN112930341A (zh) 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010192A1 (en) * 1990-12-04 1992-06-25 H. Lundbeck A/S Indan derivatives
WO2005016901A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Also Published As

Publication number Publication date
WO2020114853A1 (en) 2020-06-11
JP7583719B2 (ja) 2024-11-14
US12071416B2 (en) 2024-08-27
JP2022509965A (ja) 2022-01-25
CN113056457A (zh) 2021-06-29
US20230159478A1 (en) 2023-05-25
EP3891134A1 (en) 2021-10-13
US20220033367A1 (en) 2022-02-03
US11535600B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
WO2024023266A1 (en) Novel compounds
JP7019000B2 (ja) 2環性複素環化合物
IL152531A (en) History of 8 - (3 - carboxyamido - 3 - phenylpropyl) - 3 - (isopropyl - 5 - methyl - H4 - 4, 2, 1 – triazole - 4 - il) - tropane, drugs containing them, their preparation and some new intermediate compounds
US12624010B2 (en) Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
CA3184924A1 (en) Immunomodulator
WO2020254697A1 (en) Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
CN113845558A (zh) 高效糖皮质激素
KR20100085142A (ko) C-met/hgfr 억제제의 다형체
JP2024500101A (ja) 化合物の固体形態
US12071416B2 (en) Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine
TW202519227A (zh) 稠環衍生物、其製備方法及其在醫藥上的應用
HK40053331A (en) Prodrugs for the treatment of cns disease
JP5181674B2 (ja) 光学活性なジヒドロピリジン誘導体の酸付加塩
WO2023118521A1 (en) Dihydro-oxazol derivative compounds
HK40053331B (en) Prodrugs for the treatment of cns disease
JP2024521129A (ja) ピラゾロヘテロアリール誘導体の薬学的に許容される塩及びその結晶形
JP2008290988A (ja) 光学活性なジヒドロピリジン誘導体の酸付加塩を含有する医薬
EA048581B1 (ru) Производные дигидрооксазола и тиомочевины или мочевины, модулирующие путь nlrp3-инфламмасомы
WO2025133307A1 (en) Heterocyclic modulators of the nlrp3 inflammasome pathway
KR20080087803A (ko) 디히드로피리딘 유도체의 산부가염
HK40070300A (en) Highly potent glucocorticoids
CN118414335A (zh) 作为Src抑制剂的化合物
EP0573548A1 (en) Neuro-protective agents.
HK1078573B (en) Tropane derivatives useful in therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053331

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210629

Assignee: NHWA PHARMA. Corp.

Assignor: H.Lundbeck gmbh

Contract record no.: X2022990000498

Denomination of invention: 4-((1R,3S)-6-Chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-(( 1R,3S)-6-Chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl- Prodrugs of 1-(methyl-d3)piperazine

License type: Exclusive License

Record date: 20220811

EE01 Entry into force of recordation of patent licensing contract
GR01 Patent grant
GR01 Patent grant